PCVX News and Press, Vaxcyte Inc. From 09/14/23

2023-09-14 13:21:48 ET Summary Sutro is developing mainly antibody-drug conjugates to address solid tumors. Their flagship molecule has shown both encouraging efficacy and concerning toxicity. The company has strengthened their balance sheet strategically, removing the short-t...

2023-08-17 18:34:35 ET Summary Vaxcyte, Inc. is a clinical-stage vaccine company developing high-fidelity vaccines for bacterial diseases. The company's Q2 2023 earnings report shows significant growth in cash and investments, indicating a solid liquidity position. Positive Ph...

2023-08-08 17:53:25 ET Vaxcyte press release ( NASDAQ: PCVX ): Q2 GAAP EPS of -$0.70 beats by $0.04 . Cash, cash equivalents and investments were $1,440.8 million as of June 30, 2023, compared to $957.9 million as of December 31, 2022. The June 30, 2023 amount includes...

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series Expected by 2025 -- -- Completed Phase 2 VAX-24 Adult Program for the Prevention of Invasive Pneumococcal Disease (IPD);...

-- Initiation of Stage 2 Approved by Independent Data Safety Monitoring Board Following Review of Stage 1 Safety and Tolerability Data -- -- The Stage 2 Portion of VAX-24 Infant Study Will Include Prevnar 20 ® (PCV20) as Study Comparator -- -- Company Expects to Ann...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

2023-06-26 11:00:02 ET Sutro Biopharma, Inc. ( NASDAQ: STRO ) and Blackstone ( BX ) announced Monday a royalty financing collaboration agreement related to future sales of products currently being developed by Vaxcyte ( PCVX ) under a license from Sutro ( STRO ). P...

2023-05-17 08:20:25 ET Summary Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, VAX-24, demonstrated robust immune responses and a favorable safety profile in its Phase 2 study in a...

2023-05-08 16:53:16 ET Vaxcyte press release ( NASDAQ: PCVX ): Q1 GAAP EPS of -$0.70. Cash, cash equivalents and investments were $949.9 million as of March 31, 2023, compared to $957.9 million as of December 31, 2022. The March 31, 2023 amount excludes the $545.1 million ...

-- Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 -- -- Full Six-Month Safety Data from Both Adult Studies Demonstrated VAX-24 S...